Ligand Pharmaceuticals Reaffirms FY19 Revenue Guidance Of $118M Which May Not Compare To The $139.25M Estimate; Affirms FY19 Adj. EPS Guidance Of $3.20 Which May Not Be Comparable To The $4.16 Estimate
Benzinga_Newsdesk